Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care in the United States and internationally. The company is headquartered in Los Angeles, California.
| Revenue (TTM) | $227.18M |
| Gross Profit (TTM) | $169.15M |
| EBITDA | $39.41M |
| Operating Margin | -8.54% |
| Return on Equity | 21.60% |
| Return on Assets | 9.48% |
| Revenue/Share (TTM) | $4.51 |
| Book Value | $2.52 |
| Price-to-Book | 2.81 |
| Price-to-Sales (TTM) | 1.59 |
| EV/Revenue | 1.21 |
| EV/EBITDA | 6.11 |
| Quarterly Earnings Growth (YoY) | -34.40% |
| Quarterly Revenue Growth (YoY) | -2.60% |
| Shares Outstanding | $50.90M |
| Float | $39.09M |
| % Insiders | 15.38% |
| % Institutions | 77.53% |
Volatility is currently expanding